MLYS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Mineralys Therapeutics Inc (MLYS) is not a strong buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. While there are positive analyst ratings and hedge fund buying trends, the company's financial performance is weak, and there are no recent news catalysts or significant trading signals to justify immediate action. The technical indicators are neutral, and the options data suggests bearish sentiment in the short term. Holding off for now would be prudent.
The MACD is positive and expanding, indicating a mild bullish momentum. However, the RSI is neutral at 49.001, and moving averages are converging, suggesting no clear directional trend. The stock is trading near its pivot level of 28.448, with resistance at 29.67 and support at 27.225.
Hedge funds are significantly increasing their positions, with a 516.79% increase in buying over the last quarter.
Analysts have raised price targets, with Stifel increasing to $52 and BofA to $46, both maintaining a Buy rating.
Weak financial performance in Q3 2025, with a net income drop of -34.45% YoY and EPS declining by -53.98%.
No recent news or congress trading activity to act as a catalyst.
Options data indicates bearish sentiment.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of -$36.93M (-34.45% YoY), and a significant EPS drop to -0.52 (-53.98% YoY). Gross margin remained at 0%.
Analysts are bullish, with Stifel raising the price target to $52 and BofA to $46. Both firms maintain a Buy rating, citing potential catalysts such as finding a commercialization partner and a cash runway into 2027.
